Dedicated to Turning Switzerland into International Preventive Medicine, Precision Health and Progressive Longevity Governance Hub





Table of Contents

Longevity Swiss Foundation - Major Goals and Mission	Paradigm Shift from Treatment to Prevention
Founding Partners	The New Frontier - from Precision Medicine to Precision Health
Longevity Swiss Foundation - Summary	Development of AI Centres for Financial Wellness
Longevity Industry in Switzerland 2019	2019 Establishment of Deep Knowledge Ventures Swiss
Major Longevity-Focused Entities in Switzerland	Longevity Development Plans Report - Analysis of Swiss Government Longevity Projects
Longevity Swiss Foundation - Major Goals and Mission	Timeline of Swiss Government Involvement in Longevity
Longevity Industry in Switzerland Analytical Report	Switzerland - Key Longevity Development Metrics
Development of Artificial Intelligence Centres for Longevity in Key Swiss BioTech R&D Hubs	Switzerland Longevity Initiatives Level of Comprehensiveness
Swiss Al Centre Ecosystem	Switzerland Age / Employment Range
Advancing the Development of Precision Health Through Al	Proposal for Cooperation and Collaboration



Longevity Swiss Foundation - Summary

I. Swiss Government Engagement on National Longevity Development Plans and Initiatives

Proactive engagement with Swiss government departments, ministries, agencies and members of Swiss Parliament to establish a framework for a National Swiss Longevity Development Plan and Industrial Strategy to grow Switzerland's Longevity ecosystem to scale and enable extension of national Health-Adjusted Life Expectancy.

II. Cross-Sector Dialogue with All Major Longevity Industry Players

A focus on cross-sector dialogue, projects and initiatives spanning government, industry, academia and other relevant spheres of activity, Longevity Swiss Foundation aims to achieve a maximum level of synergy and convergence, growing every aspect of Switzerland's Longevity ecosystem to scale.

III. Coordinated Development of AI Centres for Longevity to Enable the Shift from Treatment to Prevention

Though the intensive application of AI to advanced biomedicine, Switzerland can lead the world in Precision Health, utilizing the latest innovations in AI, Longevity, Biomarkers of Ageing and Advanced Biomedicine to become nation leading the world in preventive, personalized and precision health care for its citizens.

IV. Support of Progressive Longevity Financial Reform to Neutralize Economic Burden of Ageing Population

Swiss Longevity Foundation will work alongside large Swiss financial institutions including pension funds, insurance companies, private wealth banks and other relevant entities to roadmap initiatives and policy proposals to turn the problem of ageing population into the economic opportunity of Healthy Longevity.

Founding Partners



Aging Analytics Agency is the world's premier provider of industry analytics on the topics of Longevity, Precision Preventive Medicine and Economics of Ageing,, renowned for its development of sophisticated comparative analytical frameworks allowing for practical and tangible forecasts to be applied to industries that are otherwise too complex for standard analytical approaches to be used in a relevant way. The company provides strategic consulting services in fields relating to Longevity, and currently serves as the primary source of analytics and data for the UK All-Party Parliamentary Group for Longevity.



Deep Knowledge Ventures Swiss is the Switzerland-based subsidiary of Deep Knowledge Ventures, a leading investment fund focused on the synergetic convergence of DeepTech verticals, frontier technologies and technological megatrends, renowned for its use of sophisticated analytical systems for investment target identification and due-diligence.. It made its first investments in the Longevity Industry in 2014, at a time when the large majority of investors still failed to consider it a serious prospect.



Biogerontology Research Foundation is the UK's charity focused on Longevity and on expediting the coming paradigm shift from disease treatment to personalized precision prevention. It was the main initial donor that provided financial and organisational support to Longevity International UK for the purpose of establishing the APPG for Longevity. It was also actively involved in the successful initiative of adding a new extension code for "ageing-related diseases" accepted in 2018 by the World Health Organization during the last revisions of its International Classification of Diseases framework



Longevity.International is an online interactive database of longevity scientists, companies, and investors. This platform allows different stakeholders in the longevity industry to connect, network, research and analyze. On the next stage this platform will also employ *cutting-edge data visualization software and a networking section* where various stakeholders within the longevity industry can connect and collaborate, where longevity companies are matched with the right investors, and where scientists can make contributions.



Longevity Swiss Foundation - Summary

I. Developing Switzerland into A Leading Cross-Sector International Hub of Longevity Politics and Precision Health

Leading Geneva-based Longevity Policy Non-profit and Think Tank working to leverage the national strengths and potentials of Switzerland in order to turn the nation into a world-leading Longevity Hub through the coordinated development of Longevity Politics and Governance, the Longevity BioTech Industry, Preventive Medicine, Precision Health and the emerging Longevity Financial Industry. Leveraging Switzerland's existing reputation as a hub for independent international policy organizations like the World Economic Forum, the United Nations, UNESCO, the World Health Organization and Others, Swiss Longevity Foundation aims to turn Switzerland into the leading international hub for cross-sector and cross-nation Longevity Development projects and initiatives.

II. Active Involvement with Swiss Governmental Ministries and Proactive Dialogue with Industry Stakeholders

Longevity Swiss Foundation will work with the participation of proactive corporate and institutional partners to interface with relevant Swiss governmental ministries, departments, agencies and members of Swiss Parliament to establish a National Swiss Longevity Development Framework, as well as the establishment of a parliamentary body equivalent to the United Kingdom's All-Party Parliamentary Group on Longevity.

III. Founding Members of Longevity Swiss Foundation Bring Years of Relevant Experience and Expertise

The Founding members and partners of Longevity Swiss Foundation bring years of relevant experience and activity to the task of coordinating these national and international Longevity Development Efforts, including Dmitry Kaminskiy, founder of Deep Knowledge Ventures (a VC firm that made its first investments into the Longevity industry in 2014, at a time when most investors did not consider it a serious prospect), Head of International Cooperation for the UK All-Party Parliamentary Group for Longevity Secretariat, Founder of Aging Analytics Agency (the main source of data and analytics for the UK APPG for Longevity) and the Biogerontology Research Foundation (leading Longevity-focused non-profit), and Stefan Hascoet, a Geneva-based financial industry professional with years of experience working for Swiss investment banks and other financial corporations and institutions).

Preventive Companies - 100 **Longevity Industry** Medicine TRANSCURE BIOCARTIS **PIQUR** Investors - 80 in Switzerland 2019 RodanoTech Research Labs - 35 ASCENEURON THE BLON xsensio - Phot Derma SA genkyotex Non-Profits - 15 PREXTON GTXmedical Governmental - 10 SENSOMETRIX Therapeutics Ltd memccare AMAL **Organizations** Therapeutics ARTHURIAN LIFE SCIENCES red alpine EXCELLNESS CeQur # II HELSINN VENTURE:: GLYCART GoBeyond 🎞 VESALIUS MC woodford Swiss Cardio Boehringer idinvest Johnson Johnson scailyte VENTURES NeoMed JUVA HUMABS BioMed Seroba. VERSANT VI High-Tech Grüncersons VERSANT Maxwell BIOSYSTEMS COVALX Venture Incubator covalys IFPMA CAuris Medical investiere venture **EV** group NOVARTIS Governmental FASTERIS ? entreprises MP Healthcare Warld Health
Organization
AREA.
SWISS **Organizations** ionctura **PPF** Companies VENTURE VI **AXOVANT** // st.gallen health bank In Pheno **SP** Wercules HIRSLANDEN SIRM **HBM Partners MacKenzie** ■ GenomSoft Investors SR-one dievini **哈** Stemedica UNI ehrbar Gene ignal CADFEM Seroba. FR DEUTSCHE DEUTSCHE INVEST CAPITAL PARTNERS **Non-Profits** ENGLE EGGEL LAB frim rfo SIRM Forbion. TVM Capital pregnoliaº **SKB** swisscom 🌘 ct atlantic BRI-SE XIGEN AescAp COVAGEN @ ETH zürich BILL&MELINDA GATES foundation x health 2030 Nestle Institute of Health Sciences CÓ CELLESTIA LS² OMEGA FUNDS Blue Ocean Kuros Biosciences Swiss Biotech BIOVALLEY NA VI lecogenics zeptosens **EVA** ■ Vontobel Fongit investiere Regenerative DORPHAN & NOVARTIS Research Labs Angel Investment OUEST Medicine VELUX STIFTUNG CARDIORENTIS endeavour vision **YCORPORATE K** Crisalix Index Ventures 袋TRANSLINK CAPITAL **Nestle** GNOTHIS Ť CILIATECH VENTECH aktiia 6 exquiron **HEALTHCARE** Colle SV HEALTH INVESTORS Personalized/Precision Meierhofer Roche Dividat AGING **EDMOND** Medicine IDUN **ANALYTICS** DE ROTHSCHI Ē **AGENCY** SONWVIEW Amazentis SWORTEC **CELL** RECEPTOR AC IMMUNE basilea DEEP ability evasensor abionic KNOWLEDGE oncoethix • **ANALYTICS** Genedata C APPLIED PHARMA RESEARCH ADR AC BIOVERSYS GONDOLA' atracsys AdipoGen[®] LONGEVITY AgeTech LIFE SCIENCES **ABCD**× CLINERION INTERNATIONAL aptissen

35 Swiss Research Labs **Focusing on Aging and Longevity**

Barral Group, ETH Zurich

UNI

De Virgilio Group, University


of Fribourg

Ewald Lab, ETH Zurich

UNIVERSITÉ

DE GENÈVE Laboratory of Regeneration

FR



Energy Metabolism

Laboratory, ETH Zurich

Klinik Im Park

Klinik Im Park

University of Parel

Prof. Michael N. Hal

Research Group, University



Regeneration Laboratory,

ETH Zurich

Laboratory of Integrative and

UNI

Prof Thomas Elatt Research

Group University of Fribourg

FR





of Friboura

University of

Department of Molecular

Mechanisms and Disease

University of Zurich

Zurich

UNI

Prof. Anna Jazwinska Miille

Research Group, University

of Friboura

FR



Laboratory, ETH Zurich

ehrbor

lab

Ehrbar Lab, University of



Clinique la Colline in Geneva







Focusing on Aging and Longevity







11th International Francophone Congress of Gerontology and Geriatrics

SFGG-SPSG

15 Conferences

69th World Health Assembly

Aging & Cognition 2019

Alzheimer's and Dementia Care

Annual Aging and Drug Discovery Forum

ETH zürich





Group Ocampo University of

Lausanne

Lingner Lab. EPFL

Department of Ecology and

Evolution, University of

Medicine

Unil





Preventive Medicine,

University of Bern

University of Basel

Prof. Christoph Handschin

Research Group, University

of Basel



University of Basel

Prof. Markus Rüegg

Research Group, University

of Basel

Eggel LAB









Biology of Aging - Gordon Research Seminar

G Gordon Research Conferences

Credit Suisse Global Supertrends Conference 2019

Integrative Biology of Aging: New Insights from Molecules to Systems

Gerontology Symposium

Next Generation Summit Investing in Longevity Forum











Personalized Oncology 2019

Precision Medicine and Personalized Health

Swiss Genomics Forum

15 Swiss Non-Profit Organizations

Focusing on Aging and Longevity

The World's Leading AI in Medicine Summit

UBS's 2018 Healthcare

41

Aging Analytics Agency

Summit

Aging Analytics Agency



and Adult Neurogenesis.

University of Geneve

SIRM Swice Institute for Renenerative Medicine

Swiss Stem Cells Biotech

The Neetlé Institute of Health Sciences

Vital-IT Competence Centre

Computational Biology

10 Swiss Government Organizations Focusing on Aging and Longevity



BaselArea.swiss

organisation

SWISS clinical



hiotechnet

Swiss Federal



Federal Department of

Economic Affairs

Education and Research



Rank



St Gallen Elderly Care

Swiss Biobanking Platform

World Health



BIOVALLEY



kealth 2030 genome center

Health 2030 Genome

Centre



Gerontological Economic

Research Organization







Regenerative Medicine

The Geneva Foundation

for Medical Education and

Swiss National Science Foundation



Swiss Society for Aging Research



Swiss Society of Gerontology

Life Sciences Switzerland

(LS2)



Foundation





The Swiss Biotech Association



Medicine • IREM





42

Velux Stiftung

Vontobel Foundation

Aging Analytics Agency

43 Aging Analytics Agency



Longevity Swiss Foundation - Scope of Activities & Agenda for 2019-2020

Seasoned and Experienced Founding Partners with Years of Experience in Supporting the Development of Government-led Longevity Development Plans and Sophisticated Longevity Industry Analytics

Aging Analytics Agency and the Biogerontology Research Foundation were instrumental in the initial groundwork and establishment of the UK APPG for Longevity, whereas Aging Analytics Agency provided key data, analytics and informational inputs for the APPG for Longevity, and whereas the Biogerontology Research Foundation provided the initial financing that enabled implementation of its first scope of activities.

The Launch of Longevity Swiss Foundation to Support the Development of Switzerland into a World-Leading Longevity Biomedicine, Policy, Politics, Governance and Progressive Financial Industry Hub

The founders and executives of these two entities have plans to establish a similarly-purposed entity in Switzerland, given that the country's policy-related ecosystem and its scientific and financial industry-related environment are quite matured, to a similar level as in the UK, which provides excellent grounds for launching a non-profit Swiss Longevity Foundation to structure the initial scope of activities and accumulate the initial budget to establish a Longevity Committee within the Swiss Parliament.

Cross-Sector Engagement with Government, Industry, Academic, Private-Sector and Public-Sector Stakeholders to Maximize the Reach and Inclusivity of the Swiss Foundation's Projects and Activities

The Longevity Swiss Foundation will simultaneously engage with a number of relevant Swiss Longevity companies and financial corporations interested in the emerging markets of Longevity Medicine, AgeTech and Longevity WealthTech including private wealth banks, insurance companies, pension funds, family offices, etc., as well as engagements with broader international organizations like the World Economic Forum, the World Health Organization, United Nations-related organizations, etc. Our aim is to establish this foundation formally by August - September 2019, and within half a year from its launch to aggregate around 200.000 CHF from approximately 10 sponsors, who will also provide active support in the form of strategic development, establishment of good relations with relevant Swiss counter-parties, and support of other matters within Switzerland generally and in Geneva, Zurich and Bern in particular, as well as in Lichtenstein, considering that the prince of Liechtenstein (Prince Michael von Lichtenstein) has already established a similar foundation within his own borders, and is very much interested in the topic of Longevity.




Joint Production of Longevity Industry in Switzerland Report by Longevity Swiss Foundation and Aging Analytics Agency

Longevity Swiss Foundation, in coordination with Aging Analytics Agency, have released a comprehensive analytical report that delivers an end-to-end landscape overview of the Longevity Industry in Switzerland, identifying all major players in the nation's Longevity ecosystem, ranging from companies to investors, governmental organizations, non-profits, R&D hubs, scientists, influencers and more, identifying key trends and outlining projections for the industry's near-future.

This report offers key insights and conclusions that can serve as major inputs for many of Longevity Swiss Foundation's major goals for its 2019 - 2020 agenda, and can serve to significantly inform the overall formulation and strategy of its initiatives to support the development of the Swiss Longevity ecosystem, help make Swiss an and international leader in Longevity biotechnology, biomedicine, policy, politic, governance and financial reform.

The report will be followed up my an extended and more comprehensive edition in Q1 2020, featuring a more sophisticated analytical framework.





Supporting the Coordinated Development of Artificial Intelligence Centres for Longevity in Key Swiss BioTech R&D Hubs

Aging Analytics Agency and Biogerontology Research Foundation were also critical in the initial stages of planning and development of the soon-to-be-launched Al Centre for Longevity and King's College London. which will will serve as a leading R&D hub and industry-academic hotspot for advanced Al-driven Al-driven personalized preventive diagnostics. prognostics and therapeutics. The main concept of precision medicine is providing health care which is individually tailored on the basis of a person's genes, lifestyle and environment. With the advances in genetics, artificial intelligence and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality. King's College is an ideal location for the first AI Centre for Longevity in the UK because it has dedicated divisions and resources both for AI and for Longevity.












ARK - AI Centre for Longevity at King's College London

End to End Precision Health and Preventive Medicine Diagnostic, Prognostic & Therapeutic Pipeline



Given Switzerland's extremely advanced state of preventive medicine clinics, as well as its extremely robust reputation for strong and effective industry-academic BioTech hubs, the Longevity Swiss Foundation has plans to support the formation and development of several AI Centres for Longevity across Switzerland, and will make this a core part of its strategic agenda for 2019-2020.





Accelerating the Development of Precision Health through AI

Al-Driven Precision Diagnostics

Al-Driven Advanced Prognostics

Personalised Treatment Optimization Al-Driven
Preventative
Treatment









- Multi-Omic Sequencing
- Continuous monitoring powered by Big Data Analytics
- Continuous monitoring of health state based on changes in biomarkers of aging


- Al-driven prognostics
- Advanced biomarker-based prognostics
- Al-driven predictive prognostics based on personalized multi-omics

- Al-driven in silico personalised treatment optimization
- Al-driven personalised in vivo drug optimization
- Treatment optimization based on patient genetics

- Maintenance state of precision health through preventive medicine
- Al-based predictions of optimal drug combination




Paradigm Shift from Treatment to Prevention



Longevity Swiss Foundation aims to be active on the frontlines of the paradigm shift from treatment to prevention, roadmapping and supporting the coordinated development of Switzerland's Preventive Personalized Preventive Medicine industry. Switzerland already boasts an extremely advanced level of precision medicine, and is home to not only some of the most sophisticated preventive medicine clinics in the world, but also to one of the highest basic levels of preventive personalised care in its standard clinics.



The New Frontier - from Precision Medicine to Precision Health



By focusing on the intensive application of AI to preventive medicine and personalized care, Switzerland can also be on the forefront of the shift from Precision Medicine to Precision Health, utilizing the latest innovations in AI, Longevity, Biomarkers of Ageing and Advanced Biomedicine to become nation leading the world in the optimization of national health and an extension of national Healthy Longevity (Health-Adjusted Life Expectancy).



Swiss Personalized Health Network (SPHN)






Source:

SPHN



Swiss BioTech Clusters and Hubs

SWISS PHARMA AND BIOTECH HOTSPOTS







Development of AI Centres for Financial Wellness

Coordinated Development of AI Centres for Financial Wellness to Enable Financial Stability Over Extended Periods of Healthy Longevity for Swiss Citizens, Applying Advances in WealthTech and AgeTech

Given both its status as an international BioTech epicentre, combined with its reputation for being one of the most progressive countries in terms of its financial industry and FinTech sector, the prospects for Switzerland to lead the world in the development of its Longevity Financial Industry are extremely strong. As a core component of its mission to develop Switzerland into a leading international Longevity Financial Industry hub, Longevity Swiss Foundation also plans on roadmapping the development of complimentary AI Centres for Financial Wellness.

II. Synergetic Development Alongside AI Centres for Longevity to Cover Full Scope of Healthy Longevity

Whereas the proposed AI Centres for Longevity would focus on optimizing health into old age, this centre would focus on the application of AI to the creation of methods and technologies to promote wellness in the elderly in all aspects of life besides health, ranging from financial wellness, continuing education, happiness, psychological well being, neuroplasticity and active social involvement.

Artificial Intelligence and Big Data Analysis to Maximize the Economic Opportunities of Extended III. Health-Adjusted Life Expectancy and to Neutralize the Economic Burdens of Ageing Population

Considering the vast amount of data and information about citizens being collected by financial institutions, telecom companies, etc., there are a large number of options and avenues for how AI, machine learning, big data analysis and other predictive analytical systems could utilize that data to create personalized recommendations for how citizens 60 years and older can optimize their lifestyles and behaviours to achieve a high degree of wellness, stability and social involvement and activity. The establishment of dedicated centres focusing on providing companies active in this space with advanced AI-driven support and solutions will help optimize products and services aiming to improve the overall, lifetime wellness of elderly individuals in all aspects of life besides health.




2019 Establishment of Deep Knowledge Ventures Swiss

Deep Knowledge Ventures recently founded a dedicated subsidiary in Switzerland, Deep Knowledge Swiss, to oversee its activities in this area, and to expand the regional scope of its investment focus to include cutting-edge startups in Switzerland operating in the segments of Longevity, AI in Healthcare, Invest-Tech and other relevant DeepTech Sectors.

Deep Knowledge Swiss will utilize its resources to assist the project through engagement with relevant Swiss-based corporate partners and institutions including VC firms, investment banks, pension funds, insurance companies and other strategic counter-parties to assist Longevity Swiss in its mission to turn Switzerland into a leading Longevity Biomedical and Financial Hub.

Deep Knowledge Ventures has long-standing experience as a prominent Longevity-focused VC fund, having made its first investments in the sector in 2014 at a time, when the vast majority of investors were still skeptical of the industry's validity. Deep Knowledge Ventures Swiss will utilize this expertise to help provide the growing Swiss Longevity Industry Landscape with relevant levels of funding and support.






National Government Development Plans Report Analyzed Swiss Government Longevity Development Projects and Initiatives

"National Longevity Development Plans Global Landscape Overview 2019" report produced by Aging Analytics Agency analyzed and ranked the government-led Longevity development efforts of several key nations including Switzerland, identifying key areas of both strength and weakness of each of the countries analyzed. The insights and conclusions derived from this analysis will be used in order to determine the specific areas of development in which Switzerland is lacking, as well as its core strengths above other nations and areas that should continue to be prioritized, in order to create strong inputs for the formulation of a Swiss Government-led National Longevity Plan to extend the nation's Health-Adjusted Life Expectancy (HALE).



National Government Longevity Development Plans: Country Scoring						
POSITION	COUNTRY	COUNTRY SCORE	POSITION	COUNTRY	COUNTRY SCORE	
1	United Kingdom	5.29	7	Hong Kong	3.41	
2	Netherlands	4.36	8	Japan	3.10	
3	Singapore	4.15	9	USA	3.07	
4	South Korea	4.00	10	Spain	1.94	
5	Israel	3.94	11	European Union	1.88	
6	Switzerland	3.93	12	China	1.85	







Timeline of Swiss Government Involvement in Longevity

2010 **National Platform for Palliative Care Strategy** The Confederation and cantons have promoted palliative care in Switzerland in a national strategy. **Elderly Care Bank established** 2012 St Gallen the first Swiss city to introduce a novel banking scheme in which retired care volunteers "deposit" hours worked looking after elderly people. **Masterplan for the Promotion of Biomedical Research** 2013 The plan impacts the entire chain, from research and development, clinical research, market entry for biomedical products, and pricing and reimbursement by social security, all the way to the availability of these products in day-to-day healthcare. **Retirement 2020** 2014 Swiss government advocates that "living longer means working longer". **Swiss** Personalized Roadmap 2016-2021 2016 Health For developing the next generation of clinical researchers Network 2017 Swiss Personalized Health Network (SPHN) established. 2017 2018 Masterplan for the Promotion of Biomedical Research renewed The VIA project launched 2018 The overall goal of the VIA project is to promote the health of older people and to strengthen their self-determination and independence in order to maintain or improve their quality of life

and overall well-being, allowing them to continue living at home for as long as possible.





Switzerland - Key Longevity Development Metrics



Life Expectancy	Both sexes life expectancy (2019)	81.8 years
	Male life expectancy (2018)	81.2 years
	Female life expectancy (2018)	85.2 years
GDP	GDP per capita, current prices (2018)	82.41 thousand (\$)
	GDP per capita, PPP (2018)	65.71 thousand (\$)
	GDP, current prices (2018)	707.54 billion (\$)
Population Ageing	Rate of population ageing	1.9 (2007-2017)
	Aged over 65 (2018)	18.34%
	Age dependency ratio (2017)	28%
Healthcare Efficiency	Health expenditure (2017)	12.3% of GDP
	Health expenditure per capita (2017)	8.009 thousand (\$)
	Healthcare efficiency score (2018)	58.4
Retirement	Total # retired	1 560 790
	Retired people proportion	18%
	Normal retirement age (Man/Woman)	65 years/ 64 years
	Early retirement age (Man/Woman)	63 years/ 61 years

Longevity Initiatives




- Age of relevant initiatives:15 years
- **3** of WHO age-friendly cities and communities
- 4 initiatives focused on non-medical improvement of quality of life
- 1 initiative focused on preventive medicine and healthcare approaches
- 2 initiatives involve research or R&D of medicines that directly impact on ageing



Switzerland Longevity Initiatives Level of Comprehensiveness








Switzerland Age/Employment Range



Fraction of the Unemployed by Age





Proposal for Cooperation and Collaboration

Longevity Swiss Foundation is interested in strategic partnerships and collaborations with a number of relevant counterparties in order to succeed in its mission to make Switzerland a renowned international Longevity hub.

[Cooperation with Governmental, International and Non-Governmental Organizations

Longevity Swiss Foundation is interested in cooperation, collaboration and initiating dialogue from a number of relevant organizations actively involved in Swiss governance, ranging from government ministries, agencies and departments, to relevant policy-focused NGOs and think-tanks, to members of Swiss Parliament in order to establish a framework for the coordinated development of the nation's Longevity politics and governance sphere.

II. Cooperation and Sponsorship with Biomedical and Financial Institutions

Longevity Swiss Foundation plans to work with a number of key Swiss Longevity Industry participants and stakeholders to develop a framework and blueprint for a Government-led National Longevity Development Plan to increase the national Health-Adjusted Life Expectancy (HALE) of all Swiss citizens. The scope of this plan also includes financial reform to boost Swiss GDP and reduce the economic burden of ageing population. In order to support this sphere of activity, Swiss Longevity Foundation is keen to work alongside large Swiss financial institutions including pension funds, insurance companies, private wealth banks and asset management firms to roadmap initiatives and policy proposals capable of turning the problem of ageing population into the economic opportunity of Healthy Longevity.

III. Donations from Individual and Institutional Sponsors

In order to bootstrap its activities in the realms of Longevity policy, politics, governance and synergetic industry development, Longevity Swiss Foundation is seeking donations from key institutional and individual sponsors that are keen to see the nation manifest its latent strengths and prospects, and become the leading Longevity nation that it has the potential to be.



Longevity Swiss Foundation

Swiss Longevity Foundation is primarily interested in strategic collaboration with Swiss Governmental, Non-Governmental and International organizations, as well as BioTech, BioPharma and Financial Corporations (including investment banks, VC firms, insurance companies, pension funds and asset management firms) on projects and initiatives related to Longevity.

Swiss Longevity Foundation is also interested in initiating dialogue with relevant Swiss governmental ministries, agencies, departments and members of Swiss Parliament on projects and initiatives that can help develop Switzerland's Longevity Biomedicine, Preventive Medicine, Precision Healthy and Longevity Financial Industries to scale in order to deliver both an increase in national Healthy Longevity as well as economic benefits to the nation itself by boosting GDP and neutralizing the economic burden of ageing population by adding extra years of healthy, functional productivity to Swiss citizens.

E-mail:	Website:
LinkedIn:	Twitter:

Dedicated to Turning Switzerland into International Preventive Medicine,
Precision Health and Progressive Longevity Governance Hub